More on BioMarin's (BMRN) Q2 beat: Total revenue growth of 10.3% Y/Y. Revenue growth by product: Naglazyme, +11.1%; Kuvan, +17.9%; Firdapse, +13.9%; Aldurazyme, -19.7%. BMRN updates the Phase1/2 study of the PARP inihibtor BMN 673: As of yesterday the RECIST response rate had risen to 50% (nine out of 18 breast cancer patients). When data was presented at ASCO in June, the RECIST rate was 39%. BMRN also says the National Breast Cancer Coalition will partner on BMN 673's development. FY13 guidance unchanged: Revenue of $530-555M, Naglazyme and Kuvan revenue of $265-285M and $155-170M respectively. Shares off 1.44% AH. "Only reiterated guidance? Today's game is beat AND raise," Adam Feuerstein says, sarcastically.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Wed, 5:17PM)
at Benzinga.com (Feb 20, 2015)
at Investor's Business Daily (Feb 19, 2015)
at CNBC.com (Jan 16, 2015)
at CNBC.com (Jan 15, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs